Fate Therapeutic Financials
This page shows Fate Therapeutic (FATE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Fate Therapeutic generated $13.6M in revenue in fiscal year 2024. This represents a decrease of 78.5% from the prior year.
Fate Therapeutic's EBITDA was -$191.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.1% from the prior year.
Fate Therapeutic generated -$123.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 10.7% from the prior year.
Fate Therapeutic reported -$186.3M in net income in fiscal year 2024. This represents a decrease of 15.7% from the prior year.
Fate Therapeutic earned $-1.64 per diluted share (EPS) in fiscal year 2024. This represents an increase of 0.0% from the prior year.
Fate Therapeutic held $36.1M in cash against $0 in long-term debt as of fiscal year 2024.
Fate Therapeutic had 114M shares outstanding in fiscal year 2024. This represents an increase of 15.5% from the prior year.
Fate Therapeutic's operating margin was -1542.6% in fiscal year 2024, reflecting core business profitability. This is down 1242.8 percentage points from the prior year.
Fate Therapeutic's net profit margin was -1366.5% in fiscal year 2024, showing the share of revenue converted to profit. This is down 1113.2 percentage points from the prior year.
Fate Therapeutic invested $135.0M in research and development in fiscal year 2024. This represents a decrease of 21.8% from the prior year.
Fate Therapeutic invested $730K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 88.1% from the prior year.
FATE Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M-8.7% | $1.9M+17.1% | $1.6M-12.4% | $1.9M-39.5% | $3.1M-54.6% | $6.8M+251.8% | $1.9M+14.9% | $1.7M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $25.8M-5.8% | $27.4M-5.9% | $29.1M-13.3% | $33.6M-3.0% | $34.6M+0.1% | $34.6M+7.7% | $32.1M+1.0% | $31.8M |
| SG&A Expenses | $10.6M-7.1% | $11.4M-16.9% | $13.8M-9.8% | $15.3M-26.6% | $20.8M+20.6% | $17.3M-17.3% | $20.9M+16.3% | $17.9M |
| Operating Income | -$34.7M+6.0% | -$37.0M+10.4% | -$41.3M+33.1% | -$61.7M-17.9% | -$52.4M-16.2% | -$45.1M+11.7% | -$51.1M-6.2% | -$48.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$32.3M+5.3% | -$34.1M+9.4% | -$37.6M+27.9% | -$52.2M-9.4% | -$47.7M-24.1% | -$38.4M+20.0% | -$48.0M-8.8% | -$44.1M |
| EPS (Diluted) | $-0.27+6.9% | $-0.29+9.4% | $-0.32+27.3% | $-0.44-10.0% | $-0.40-21.2% | $-0.33+29.8% | $-0.47-4.4% | $-0.45 |
FATE Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $343.7M-7.5% | $371.6M-6.8% | $398.7M-9.5% | $440.7M-11.0% | $495.0M-6.4% | $528.8M-7.2% | $569.9M+12.6% | $506.2M |
| Current Assets | $221.3M-4.0% | $230.4M-7.2% | $248.2M-15.0% | $291.9M-5.9% | $310.3M-2.8% | $319.4M-19.0% | $394.4M+19.0% | $331.5M |
| Cash & Equivalents | $40.6M-1.5% | $41.2M-8.2% | $44.9M+24.6% | $36.1M-4.9% | $37.9M+2.7% | $36.9M-69.6% | $121.3M+189.8% | $41.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $682K-51.1% | $1.4M-42.0% | $2.4M-32.0% | $3.5M-14.2% | $4.1M+293.8% | $1.0M+22.1% | $858K-53.0% | $1.8M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $109.6M-0.6% | $110.3M0.0% | $110.3M-9.6% | $122.0M-8.0% | $132.6M+0.6% | $131.8M-8.3% | $143.8M+4.3% | $137.8M |
| Current Liabilities | $28.1M-2.0% | $28.7M+1.8% | $28.2M-26.9% | $38.5M+2.9% | $37.4M+7.6% | $34.8M-23.3% | $45.4M+16.1% | $39.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $234.1M-10.4% | $261.4M-9.4% | $288.4M-9.5% | $318.7M-12.0% | $362.3M-8.7% | $397.0M-6.8% | $426.1M+15.7% | $368.4M |
| Retained Earnings | -$1.5B-2.2% | -$1.5B-2.4% | -$1.4B-2.7% | -$1.4B-3.9% | -$1.3B-3.7% | -$1.3B-3.1% | -$1.3B-4.0% | -$1.2B |
FATE Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$33.8M | N/A | N/A | N/A | -$33.4M | N/A |
| Capital Expenditures | N/A | N/A | $1.2M | N/A | N/A | N/A | $86K | N/A |
| Free Cash Flow | N/A | N/A | -$35.0M | N/A | N/A | N/A | -$33.4M | N/A |
| Investing Cash Flow | N/A | N/A | $42.7M | N/A | N/A | N/A | $17.3M | N/A |
| Financing Cash Flow | N/A | N/A | $0 | N/A | N/A | N/A | $95.5M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
FATE Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1995.1%-56.6pp | -1938.5%+595.5pp | -2534.1%+785.7pp | -3319.8%-1615.9pp | -1703.9%-1038.1pp | -665.7%+1987.2pp | -2652.9%+215.6pp | -2868.4% |
| Net Margin | -1852.4%-65.8pp | -1786.6%+522.9pp | -2309.4%+494.5pp | -2803.9%-1252.9pp | -1551.0%-983.6pp | -567.4%+1926.3pp | -2493.7%+138.9pp | -2632.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -9.4%-0.2pp | -9.2%+0.3pp | -9.4%+2.4pp | -11.8%-2.2pp | -9.6%-2.4pp | -7.3%+1.1pp | -8.4%+0.3pp | -8.7% |
| Current Ratio | 7.87-0.2 | 8.04-0.8 | 8.81+1.2 | 7.58-0.7 | 8.29-0.9 | 9.18+0.5 | 8.69+0.2 | 8.48 |
| Debt-to-Equity | 0.47+0.0 | 0.42+0.0 | 0.380.0 | 0.38+0.0 | 0.37+0.0 | 0.330.0 | 0.34-0.0 | 0.37 |
| FCF Margin | N/A | N/A | -2148.9% | N/A | N/A | N/A | -1736.9% | N/A |
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks.
Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.
Operating cash flow vs net income. Above 1.0x = cash-backed earnings.
Similar Companies
Frequently Asked Questions
What is Fate Therapeutic's annual revenue?
Fate Therapeutic (FATE) reported $13.6M in total revenue for fiscal year 2024. This represents a -78.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Fate Therapeutic's revenue growing?
Fate Therapeutic (FATE) revenue declined by 78.5% year-over-year, from $63.5M to $13.6M in fiscal year 2024.
Is Fate Therapeutic profitable?
No, Fate Therapeutic (FATE) reported a net income of -$186.3M in fiscal year 2024, with a net profit margin of -1366.5%.
What is Fate Therapeutic's earnings per share (EPS)?
Fate Therapeutic (FATE) reported diluted earnings per share of $-1.64 for fiscal year 2024. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Fate Therapeutic's EBITDA?
Fate Therapeutic (FATE) had EBITDA of -$191.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Fate Therapeutic's operating margin?
Fate Therapeutic (FATE) had an operating margin of -1542.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Fate Therapeutic's net profit margin?
Fate Therapeutic (FATE) had a net profit margin of -1366.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Fate Therapeutic's free cash flow?
Fate Therapeutic (FATE) generated -$123.6M in free cash flow during fiscal year 2024. This represents a 10.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Fate Therapeutic's operating cash flow?
Fate Therapeutic (FATE) generated -$122.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Fate Therapeutic's total assets?
Fate Therapeutic (FATE) had $440.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Fate Therapeutic's capital expenditures?
Fate Therapeutic (FATE) invested $730K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Fate Therapeutic spend on research and development?
Fate Therapeutic (FATE) invested $135.0M in research and development during fiscal year 2024.
How many shares does Fate Therapeutic have outstanding?
Fate Therapeutic (FATE) had 114M shares outstanding as of fiscal year 2024.
What is Fate Therapeutic's current ratio?
Fate Therapeutic (FATE) had a current ratio of 7.58 as of fiscal year 2024, which is generally considered healthy.
What is Fate Therapeutic's debt-to-equity ratio?
Fate Therapeutic (FATE) had a debt-to-equity ratio of 0.38 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Fate Therapeutic's return on assets (ROA)?
Fate Therapeutic (FATE) had a return on assets of -42.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Fate Therapeutic's cash runway?
Based on fiscal year 2024 data, Fate Therapeutic (FATE) had $36.1M in cash against an annual operating cash burn of $122.9M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Fate Therapeutic's Piotroski F-Score?
Fate Therapeutic (FATE) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.
Are Fate Therapeutic's earnings high quality?
Fate Therapeutic (FATE) has an earnings quality ratio of 0.66x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.
How financially healthy is Fate Therapeutic?
Fate Therapeutic (FATE) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.